Aktienanalyse zu Tempus AI Inc (TEM)TEMTempus AI Inc

Tempus AI, Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. It offers AI-enabled precision medicine solutions to physicians to deliver personalized patient care and, in parallel, facilitates discovery, development and delivery of optimal therapeutics. It provides three product lines: Genomics, Data and artificial intelligence applications (AI). The Genomics product line leverages its laboratories to provide next generation sequencing (NGS) diagnostics, polymerase chain reaction, profiling, molecular genotyping and other anatomic and molecular pathology testing. The data generated in its lab or ingested into its platform is structured and de-identified, prior to commercialization. Its AI Applications is focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools. It operates in the Healthcare sector.

Tempus AI Inc is a good buy right now, trading at $64.04 with a strong analyst price target of $80, indicating a potential upside of 24.3%. The recent FDA clearance for their AI software enhances their market position, while a gross margin of 64.45% shows solid profitability potential. However, the main risk is the high debt-to-equity ratio of 305.82%, which indicates financial leverage that could impact stability.